A Phase 3 interventional study of Intravenous Cisplatin & etoposide and Intravenous Cisplatin & etoposide along with oral cyclophosphamide in Lung Cancer, Squamous Cell Carcinoma of the Lung and Locally Advanced and Metastatic Squamous Cell Carcinoma of the Lung, sponsored by Swami Rama Cancer Hospital and Research Institute. Status unknown at 1 site in India. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-09-20.
Sponsored by Swami Rama Cancer Hospital and Research Institute · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies testing cisplatin in Lung Neoplasms — 5 open to participants now, 9 under way, 2 of them phase 3. Cisplatin · Lung Neoplasms.
Among the 115 studies testing cisplatin in Lung Neoplasms, this one is the 39th largest by planned enrollment of the 99 interventional ones that give a count, is one of 2 that started in 2013, is one of 22 in phase 3, and was the 93rd registered.
5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.
Browse Lung Neoplasms studies →5 of the 115 studies testing cisplatin in Lung Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Centre Leon Berard · Sites in France, Réunion
Ages 18+
AstraZeneca · Sites in United States, Belgium, Canada and 9 more countries
Ages 18–95
Fudan University · Sites in China
Ages 18–70
University of Vermont
Ages 18+
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Ages 18–70
By country, each count listing its studies:
Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →
Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 74 · Phase 3 24
First in 1993; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 60 across 3,657 interventional studies indexed under Lung Neoplasms.
Median enrollment 47 across the 99 interventional studies. Of the 85 that completed or were terminated, 24 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 115 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Swami Rama Cancer Hospital and Research Institute as lead sponsor.
Swami Rama Cancer Hospital and Research Institute has 1 study filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
1 of the studies testing cisplatin in Lung Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04491942National Cancer Institute (NCI)Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 115 studies testing cisplatin in Lung Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Treatment of locally advanced and metastatic squamous cell carcinoma of the lung involves the use of chemotherapy as the therapeutic mainstay. Platinum-etoposide regimens (such as cisplatin-etoposide) are the most commonly used chemotherapeutic regimen, which is delivered intravenously in the standard three-weekly intervals.
Recent interest in oral metronomic chemotherapy has arisen, especially due to its beneficial effects in delaying disease progression among heavily pre-treated patients with various malignancies.
This study attempts to combine the use of metronomic chemotherapy concurrently during standard intravenous chemotherapy.
Adenocarinoma and squamous cell carinoma are the two major types of non-small cell lung carcinoma. While patients with adenocarcinoma of the lung have the feasibility of treatment with tyrosine kinase inhibitors, the patients with squamous cell carcinoma can only be treated with standard chemotherapy due to the ineffectiveness of tyrosine kinase inhibitors. Thus, the current standard is to treat patients of squamous cell lung cancers with standard intravenous chemotherapy, which is mostly delivered once in three weeks.
Metronomic chemotherapy, meaning the delivery of low doses of chemotherapy, often by an oral approach, on a daily basis so as to maintain a low but definite level of the chemotherapy has received great interest in recent times due to its beneficial effects in terms of extending progression free survival among patients of various malignancies, even after failure with previous conventional therapies. Metronomic chemotherapy is proposed to be active by alternate mechanisms, such as the predominant anti-angiogenic effect, in contrast to the cytotoxic and genotoxic effects of standard chemotherapy.
Metronomic chemotherapy with oral cyclophosphamide has been shown to extend progression free survival when used as a single agent in various malignancies. Given the fact that progression after varying time spans is a rule (rather than the exception) among patients of squamous cell lung cancer being treated with conventional chemotherapy, we have intended to combine the use of oral metronomic chemotherapy given concurrently with standard intravenous cisplatin-etoposide based chemotherapy. We intend to observe a prolongation of progression free survival.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive standard intravenous chemotherapy based on cisplatin and etoposide.
Drug: Intravenous Cisplatin & etoposide
Patients will receive both intravenous (cisplatin and etoposide based) and metronomic chemotherapy (with oral cyclophosphamide).
Drug: Intravenous Cisplatin & etoposide along with oral cyclophosphamide
Drug pages: Cisplatin · Etoposide
Patients will receive standard intravenous cisplatin and etoposide based chemotherapy, for a total of six cycles, delivered at three-weekly intervals. In each cycle, the dose of cisplatin will be at 50mg/m2 on days 1 \& 2. The dose of etoposide will be 100mg/m2 on days 1, 2 \& 3.
Also known as: Control arm, Standard intravenous chemotherapy
Drug pages: Cisplatin · Etoposide · Cyclophosphamide
Patients will be treated with oral cyclophosphamide at a daily dose of 50mg. Patients will also receive standard intravenous cisplatin and etoposide based chemotherapy, for a total of six cycles, delivered at three-weekly intervals. In each cycle, the dose of cisplatin will be at 50mg/m2 on days 1 \& 2. The dose of etoposide will be 100mg/m2 on days 1, 2 \& 3.
Also known as: Experimental arm, Intravenous with metronomic chemotherapy
Progression free survival
Time frame: 12 months on average
Response rate
Time frame: 12 months on average
The record gives a start of Oct 2013, a primary completion of Jun 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cisplatin · Etoposide · Cyclophosphamide